Market Access Impact: Type 2 Diabetes Mellitus (EU5) 2016

Saturday, November 18, 2017 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 17, 2017 /PRNewswire/ --

Description

How are market barriers impacting the host of European T2DM brands?

Read the full report: https://www.reportlinker.com/p04833572

It's a fact of life that non-clinical constraints such as cost, availability and administration are influencing prescribing trends for Type 2 Diabetes Mellitus

(T2DM) drugs. If you're looking for fresh insight and inspiration to boost your market access strategy and market share, this report is the ideal solution. Market Access Impact: T2DM (EU5) pinpoints the specific barriers affecting 12 named drugs from the leading manufacturers including Novo Nordisk,AstraZeneca, Boehringer Ingelheim and Novartis. Find out now exactly what is driving doctors' prescribing activity, both for your drugs and your competitors.

Top Takeaways - Three brands dominate: Which drugs are most doctors prescribing and why? And of the rest, which are also considered and which are rejected? - Physicians hands are tied: In 2/3rds of cases, doctors are unable to prescribe their first choice. What are the specific barriers in place and which drugs are impacted? - Good news for some but not all: Market barriers helping some drugs to gain share at the expense of other brands – but most are losing out. How is yours doing? - Closely fought positions: Competition is fierce but which three brands are either currently used or actively considered by nearly all the physicians surveyed? - One to watch: Only one drug is gaining share from every other brand in the survey. What is their market barrier secret weapon? - Turning negatives to positives: Physicians said they would not consider using some brands. Which drugs are affected and what is prompting this negative response?

Insight into 12 Major T2DM Drugs - Januvia (sitagliptin; Merck & Co) - Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim) - Galvus (vildagliptin; Novartis) - Invokana (canagliflozin; Johnson & Johnson) - Jardiance (empagliflozin: Eli Lilly/Boehringer Ingelheim) - Forxiga (dapagliflozin; AstraZeneca) - Victoza (liraglutide; Novo Nordisk) - Trulicity (dulaglutide; Eli Lilly) - Toujeo (insulin glargine; Sanofi) - NovoRapid (insulin aspart; Novo Nordisk) - Tresiba (insulin degludec; Novo Nordisk) - Xultophy (insulin degludec/liraglutide; Novo Nordisk)

Exploring Important Market Access Issues Market Access Impact: T2DM explores key issues affecting drug manufacturers. You'll learn: - How barriers affect market access: - What brands do doctors prescribe the most? - How many prescriptions do barriers affect? - Which barriers have the biggest impact? - How barriers affect your brand: - How many doctors prescribe your brand? How many don't, but would consider it? - Why don't doctors prescribe your brand? What do they prescribe instead? - Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge We surveyed surveyed 150 diabetologists and primary care physicians in the EU5 (30 from each country: France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world. All respondents have: - Been practicing for 2+ years - Prescribed at least one of the listed products - Seen at least 5 patients with multiple myeloma in total in the last month We conducted the survey between September 5th and 8th, 2016.

Read the full report: https://www.reportlinker.com/p04833572

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/market-access-impact-type-2-diabetes-mellitus-eu5-2016-300558787.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store